The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| VAXCYTE INC | COM | 92243G108 | 27,757 | 1,405,421 | SH | DFND | 1 | 0 | 1,405,421 | 0 | |
| ENTASIS THERAPEUTICS HLDGS I | COM | 293614103 | 2,517 | 1,176,378 | SH | DFND | 1 | 0 | 1,176,378 | 0 | |
| INOZYME PHARMA INC | COM | 45790W108 | 31,505 | 1,591,154 | SH | DFND | 1 | 0 | 1,591,154 | 0 | |
| KARUNA THERAPEUTICS INC | COM | 48576A100 | 109,254 | 908,708 | SH | DFND | 1 | 0 | 908,708 | 0 | |
| ARCUTIS BIOTHERAPEUTICS INC | COM | 03969K108 | 16,462 | 569,041 | SH | DFND | 1 | 0 | 569,041 | 0 | |
| ALIGOS THERAPEUTICS INC | COM | 01626L105 | 19,933 | 876,548 | SH | DFND | 1 | 0 | 876,548 | 0 | |
| AKOUOS INC | COM | 00973J101 | 24,884 | 1,794,088 | SH | DFND | 1 | 0 | 1,794,088 | 0 | |
| FUSION PHARMACEUTICALS INC | COM | 36118A100 | 17,135 | 1,598,379 | SH | DFND | 1 | 0 | 1,598,379 | 0 | |
| BOLT BIOTHERAPEUTICS INC | COM | 097702104 | 62,248 | 1,891,467 | SH | DFND | 1 | 0 | 1,891,467 | 0 | |